Phase II study to evaluate the efficacy of NGX 426 in patients with acute migraine

Trial Profile

Phase II study to evaluate the efficacy of NGX 426 in patients with acute migraine

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2007

At a glance

  • Drugs Dasolampanel (Primary)
  • Indications Migraine
  • Focus Therapeutic Use
  • Sponsors TorreyPines Therapeutics Inc
  • Most Recent Events

    • 31 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top